Option-to-acquire structures stay uncommon amid biotech's busy M&A season

Biotech companies are experiencing one of the busiest deal-making years on record, with a flood of announced mergers and acquisitions.

Two recent transactions have highlighted the option-to-acquire model, where a buyer secures the right to purchase a target at a later date rather than completing an immediate outright purchase.

Analysts note that this structure remains uncommon because it adds complexity and uncertainty, but it may appeal to investors seeking flexibility in a volatile market.